×

Serwis używa ciasteczek ("cookies") i podobnych technologii m.in. do utrzymania sesji i w celach statystycznych. • Ustawienia przeglądarki dotyczące obsługi ciasteczek można swobodnie zmieniać. • Całkowite zablokowanie zapisu ciasteczek na dysku komputera uniemożliwi logowanie się do serwisu. • Więcej informacji: Polityka cookies OPI PIB

×

Regulamin korzystania z serwisu PBN znajduję się pod adresem: Regulamin serwisu

Szukaj wśród:
Dane publikacji

DETERMINATION OF N,N - DIMETHYL - 2 - PHENYLPROPAN - 1 - AMINE B Y GC - MS SYSTEM IN EXCRETION STUDY

Rozdział
2015 angielski
Liczba arkuszy: 0,1
Link do publicznie dostępnego pełnego tekstu
Cechy publikacji
-
  • Abstrakt
  • Zrecenzowana naukowo
  • Konferencyjna
Dyscypliny naukowe
-
Chemia
Słowa kluczowe
-
Dane konferencji
-
  1. EUROANALYSIS 2015, 18th edition of EuroAnalysis the European Conference on Analytical Chemistry
  2. 2015-09-06 - 2015-09-10
  3. Bordeaux, Francja
Abstrakty ( angielski )
-
N,N-dimethyl-2-phenylpropan-1-amine (NN-DMPPA) is a new designer stimulant in sport. It is an analogue of amphetamine and can be attached to the phenethylamines in the Chemicals and Drugs Classification. Although the stimulating effect of NN-DMPPA on the human organism is not known, it can be expressed as ‘a designer stimulant’ on the basis of its similarity in the structure to other stimulants on the List of Prohibited Substances and Methods (established by the Word Anti-Doping Agency, WADA). NN-DMPPA was in dicated as a new designer agent by the WADA- accredited anti-doping laboratory in Warsaw (the Department of Anti-Doping Research, Institute of Sport in Poland) during the routine anti-doping control in 2013 and 2014 four times. Moreover, the researches carried out by this laboratory pointed out the presence of NN-DMPPA in some nutritional supplement with the lack of labelling of this substance. In the present work the determination of NN-DMPPA in urine by the GC-MS system has been applied to the excretion study following single oral supplement dose. The method has been validated and acceptable validation parameters have been received (e.g. RSD below 1.6%, LOQ of 6.5 ng·mL-1 and the uncertainty of NN-DMPPA determination of 7.1% for 1000 ng·mL-1, 95 % confidence coefficient, n = 4). In the excretion study one ‘NOXPUMP’ suplement with NN-DMPPA was ingested by three volunteers. Following administration of this supplement the excretion parameters as the maximum concentration of NN-DMPPA in urine and the time for the maximum height of the excretion peak have been indicated.
Zacytuj dokument
-